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.org (J. Peters).Summary Recombinant interferon-a (rINF-a) is an immunomodulator used in the
treatment of various conditions, including viral infections and malignancies. The use
of rINF-a has been associated with the development of sarcoidosis in recent case
reports. In this series, we report the incidence of sarcoidosis in recipients of rINF-a
for hepatitis C viral (HCV) infection at our institution. We also review the 57
additional cases of sarcoidosis associated with rINF-a described in the literature,
including clinical presentation, radiographic findings, management, and outcomes,
and discuss the potential mechanisms by which rINF-a may lead to the development
of sarcoidosis.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Recombinant interferon-a (rINF-a) is an immuno-
modulator used in the treatment of various condi-
tions, including viral infections and malignancies.
The inclusion of this agent in the treatment
regimens of such diseases, and of viral hepatitis in
particular, has been associated with improvedElsevier Ltd. All rights reserv
732 7420;
ners.org (H.J. Goldberg),outcomes, though also with significant side effects.
Recent case reports describe the onset of systemic
sarcoidosis in patients managed with r-INF-a for
the above conditions. In this case series, we
report the incidence of sarcoidosis in recipients of
rINF-a for hepatitis C viral (HCV) infection at our
institution. We also review the 57 additional cases
of sarcoidosis associated with rINF-a described in
the English literature, including clinical presenta-
tion, radiographic findings, management, and out-
comes, and discuss the potential mechanisms by
which rINF-a may lead to the development of
sarcoidosis.ed.
ARTICLE IN PRESS
H.J. Goldberg et al.2064Methods
Case series
Of all individuals treated for chronic active HCV
infection at University Hospital of Bexar County,
TX, and the Audie L. Murphy Veterans’ Administra-
tion Hospital in San Antonio, TX between 6/1/02
and 6/1/05, we included in our subject cohort any
patients referred to specialists by their primary or
GI physicians for potential manifestations of sar-
coidosis. We collected available data for these
patients relating to clinical presentation, labora-
tory, spirometric, and radiographic evaluations, as
well as diagnostic and therapeutic interventions,
for this report. Based upon these findings, we
calculated the incidence of sarcoidosis in our
population of patients who received rINF-a, and
compared this incidence to those HCV patients
never exposed to rINF-a.Literature review
We performed a Medline search and cross-refer-
ence of ‘‘Interferon’’ and ‘‘Sarcoidosis’’ to identify
case reports of an association between these
disorders in the literature. Reports of sarcoidosis
development in association with rINF-a with an
abstract or full text available in English were
reviewed, and available data regarding clinical
presentation, radiographic findings, management,
and outcomes are reported here.Statistics
A two-sided comparison of population proportions
was used to compare the incidence of sarcoidosis in
patients with HCV at our institutions that wereFigure 1 Chest CT of patient 1 demonstrating diffusexposed to rINF-a with that of those who never
received this medication.Results
Of 667 patients treated with rINF-a for HCV at our
institution, we identified three cases of biopsy-
proven sarcoidosis (incidence 0.44%). Two patients
were African American (2/63, incidence 3.17%) and
one Caucasian (1/267, incidence 0.37%). None of
the 332 Hispanic or 5 Asian patients who received
rINF-a was identified as suffering from sarcoidosis.
No cases of sarcoidosis were observed among 3862
patients with HCV who never received rINF
(Po0.0004.) Of this group, 50% were Hispanic,
40% Caucasian, and 10% African American. Our
three cases are briefly described here.Case 1
A 54-year-old African American male, diagnosed
with chronic, active HCV by liver biopsy, was
initiated on INF-a plus ribavirin. Two months later,
he developed a cough productive of clear sputum
and dyspnea on exertion. Physical examination
revealed no adenopathy and lungs were clear to
auscultation.
Pulmonary function tests demonstrated mild
obstruction, normal lung volumes, and normal
diffusing capacity. Chest imaging showed a diffuse
nodular infiltrate, with minimal bilateral hilar and
mediastinal lymphadenopathy (Fig. 1). No evidence
of sarcoidosis was seen on review of the patient’s
liver biopsy. The patient underwent fiberoptic
bronchoscopy with trans-bronchial biopsy, which
revealed non-necrotizing sarcoidal granulomas with
many multinucleated giant cells (Fig. 2). Cultures
showed no growth. The patient’s rINF-a wase parenchymal nodularity and hilar adenopathy.
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Figure 2 (a) A transbronchial biopsy specimen from patient 1 revealed non-casseating granulomata with multi-
nucleated giant cells. (b) A skin biopsy from patient 2 showed sarcoidal type granulomas with negative microbial stains.
Sarcoidosis after treatment with interferon-a 2065discontinued, with resolution of symptoms and
radiographic findings.Case 2
A 54-year-old African American male was diagnosed
with chronic active HCV by liver biopsy and started
on pegylated INF-a and ribavirin. Six months later,
he developed dyspnea and a cough productive of
clear sputum. One month subsequent to this, he
complained of pain and swelling at a tattoo site.
Physical examination showed no palpable lympha-
denopathy and lungs were clear to auscultation.
Skin exam was notable for eczematous patches and
plaques at the patient’s tattoo site.
On pulmonary function testing, the patient had
mild obstruction with normal lung volumes and
diffusing capacity. Chest radiography showed in-
numerable tiny interstitial nodules throughout the
lungs bilaterally, bilateral symmetric hilar adeno-
pathy, and multiple sub centimeter lymph nodes
throughout the mediastinum. A skin biopsy re-
vealed sarcoidal type non-necrotizing granulomas
in the subcutaneous tissue (Fig. 2). Staining
revealed no organisms. The patient’s anti-viral
therapy was discontinued, with resolution of skin
findings 2 months later and improvement in
pulmonary symptoms and radiographic findings by
6 months.Case 3
A 44-year-old Caucasian female was diagnosed with
chronic active HCV by liver biopsy and initiated on
rINF-a and ribavirin. One month later, she devel-
oped a rash. Physical exam revealed no evidence of
lymphadenopathy and lungs were clear to ausculta-
tion. Skin exam was notable for subcutaneous
nodules over the upper extremities. Chest radio-
graphy showed sub centimeter hilar and mediast-inal lymphadenopathy. The patient underwent
excision of a subcutaneous nodule from her right
upper extremity, which showed non-casseating
granulomata with absence of growth on cultures.
Her antiviral-therapy was discontinued, with initial
improvement in her symptoms. Symptoms re-
curred, however, 6 months after discontinuation
of rINF-a. Her management is ongoing.Discussion
Sixty cases of sarcoid development after the
institution of rINF-a therapy have been reported
in the English literature,1–52 including the indivi-
duals described above. The mean age of patients
was 49.8 years (range 26–67). The race and gender
of the subjects was not commonly reported. While
the majority of individuals (52/60) received ther-
apy for HCV, sarcoidosis has also developed in
association with the management of Hepatitis B
infection,1 lymphoproliferative malignancies2–7 and
other hematologic conditions.8
The mean time to onset of symptoms was 11.4
months (range 1–60 months). A number of patients
experienced no symptoms of sarcoidosis during
initial treatment, but developed symptoms during
repeated courses of INF-a.16–18 In some instances,
symptoms developed from as early as one week to
as late as 3 years after discontinuation of the
drug.5,22–25
The most commonly affected organs included
skin and lungs, though many other organ systems
have also been involved (see Table 1). Other
manifestations of disease included erythema nodo-
sum,23,29,32,33 hypercalcemia25,29,34,35 and Lofg-
ren’s Syndrome.11,22,23,36
The majority of patients underwent both chest
X-ray and CT scanning during their evaluations.
Lymphadenopathy was found most often (24/46
patients), either alone or in combination with
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Table 1 Other manifestations of sarcoidosis after
rINF-a.
Organ Number of
cases
Clinical manifestations
CNS/
PNS
2 Facial nerve palsy,
neuropathy
Eye 2 Uveitis
Kidney 2 Hypercalcuria, acute renal
insufficiency
Parotid 2 Swelling, salivary
hyperamylasemia
Heart 3 Atrio-ventricular block
Joint 3 Arthralgias, arthritis
Liver 5 Transaminitis, non-
casseating granulomata
CNS: central nervous system; PNS: peripheral nervous
system.
H.J. Goldberg et al.2066parenchymal abnormailites. Parenchymal involve-
ment included diffuse nodularity (15/46 patients)
and reticulo-nodular infiltrates (15/46) most com-
monly. Seven of the 46 patients had normal chest
radiography at the time of diagnosis.
Only rare case reports included data on pulmon-
ary function in these patients. Results included
obstruction, decreased carbon monoxide diffusing
capacity, and/or restriction either alone or in
combination.5,12,22,33,36 Diagnosis was most often
accomplished via skin25,51 or lung biopsies.15,51
Lymph node biopsy and liver biopsy were each
utilized in six and four cases, respectively. The
most common method of management was dis-
continuation of therapy, either alone or in combi-
nation with systemic corticosteroids. Two patients
were treated with dose reduction3,38 and three
required no interventions.12,36,39 The majority of
patients experienced resolution or improvement in
symptoms; however, seven suffered persistent or
relapsing courses.
The mechanisms by which cytokine production
influences granuloma formation in systemic sarcoi-
dosis are currently under investigation. Sarcoidosis
is thought to result from a cell mediated T helper 1
response.40 IL-2,41 IL-12, and IL-1842 levels are
increased in broncho-alveolar lavage (BAL) fluid of
patients with sarcoidosis, supporting the conten-
tion that a Th1 response is involved with sarcoid
pathogenesis.42–45 Inui et al.45 demonstrated that
stimulation of BAL fluid cells isolated from patients
with sarcoidosis led to increased IFN-g production
and an increased ratio of IFN-g/IL-4 from CD-4 cells
compared to normal controls.
INF-a may increase IFN-g and IL-2 levels, thus
promoting granuloma formation.4 Exogenous INF-a
has been implicated in the alteration of lymphocyteprofiles in BAL fluid.47 Furthermore, Akahoshi et al.
demonstrated that a particular single nucleotide
polymorphism in the INF-a gene led to increased
INF-a levels and an increased incidence of sarcoi-
dosis. Thus, exposure to exogenous INF-a could
theoretically contribute to the development of
sarcoidosis by its effects on cytokines that stimu-
late the T helper 1 pathway.
Our study may underestimate the incidence of
sarcoidosis in both the interferon exposed and
unexposed groups, as only individuals referred to
specialists and with biopsy proven sarcoidosis were
included in our analysis. In addition, while our
review suggests that exposure to rINF-a may
contribute to the development of sarcoidosis in
patients with HCV, the severity of their underlying
liver disease and concomitant medication use could
be contributing factors. A conclusive association
cannot be established by these reports, however.
Prior studies have suggested that HCV infection in
itself may increase the risk of sarcoidosis, inde-
pendent of therapy.15 The threefold increased
incidence of sarcoidosis in our African American
population treated with rINF-a as compared to
those never exposed to the drug argues against
infection with HCV as the sole etiology for the
development of sarcoidosis. Moreover, most pa-
tients in our search stabilized or improved after
rINF-a was discontinued, despite continued active
HCV infection.
Our case series reflects the characteristics of
sarcoidosis that seem to be typical in association
with rINF-a therapy, but that differ from other
forms of systemic sarcoid. Diffuse nodular parench-
ymal abnormalities, while uncommonly seen in
sarcoid patients in general, were observed in two
of our three patients and in one third of cases in our
literature review. In addition, the relatively mild
course of disease and rapid response to disconti-
nuation of therapy observed in our case series and
in the majority of cases reported is in contra-
distinction to the natural history of the disease in
general. Further study regarding the potential
contribution of HCV infection and its therapy, as
well as the genetic predisposition in this popula-
tion, warrants further study.References
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